Study S000074

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT07284979
Acronym: KaiNETIC-3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 1270
Start: 2025-12-30
Primary completion: 2028-03
Lead sponsor: Kailera
Conditions: Obesity
Interventions: DRUG:Ribupatide; DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: CTIS:2025-523511-11-00; NIH:2025

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 76 [Baseline, Week 76]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.